Two-Year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study.

Trial Profile

Two-Year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Male osteoporosis; Osteoporosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2012 Results of the 2-year open-label extension study published in Bone.
    • 01 Mar 2009 Results of a pharmacogenomics substudy published in Calcified Tissue International, 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top